IGRT treatment with simultaneous integrated boost as dose escalation for patients with cervical cancer

IGRT treatment with simultaneous integrated boost as dose escalation for patients with cervical cancer - OTI-L1

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00019044

Enrollment

Registered

2019-11-13

Start date

2015-01-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CERVICAL CANCER C53

Interventions

Group 1: Radiation Therapy with simultaneous integrated boost technique

Eligibility

Sex/Gender

Female

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: - Stage IIb and IV Cervix cancer Patient - ECOG (Eastern Cooperative Oncology Group): 1-2 - GFR (glomerular filtration rate): over 30 ml/min

Exclusion criteria

Exclusion criteria: ECOG: 3 GFR: under 30 ml/min

Design outcomes

Primary

Measure	Time frame
Toxicity, Local Control, EORTC-QLQ 30 and CX-24 questionnaire during treatment and MRI Control every three month after treatment. After one year every 6 month.	—

Secondary

Measure	Time frame
Progression Free Survival	—

Countries

Hungary

Contacts

Public ContactLocsei Zoltán

Universität von Pécs, Klinisches Zentrum, Onkotherapeutisches Institut

locsei.zoltan@pte.hu+3672536480

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026